GlassScriptPhysician profile
Han-Jong Koh
NPI 1619962263
$1,431.95
in general payments reported to CMS, 2019-2025
23 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $149 · 2021: $16.84 · 2022: $67.48 · 2024: $23.36 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.81 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.92 | 2019-2025 | Ozempic |
| Amgen INC. | $118.16 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $106.85 | 2019-2025 | |
| Medtronic, INC. | $86.01 | 2021-2025 | Inceptiv |
| Astrazeneca Pharmaceuticals LP | $82.88 | 2019 | |
| Astellas Pharma US INC | $80.89 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $71.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.45 | 2019-2020 | |
| Lilly USA, LLC | $58.13 | 2019-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $56.48 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.56 | 2019 | |
| Pfizer INC. | $47.75 | 2019-2025 | |
| Amarin Pharma, INC. | $43.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.79 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $25.47 | 2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $25.08 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $23.36 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Genentech USA, INC. | $19.64 | 2019 | |
| Bausch Health US, LLC | $18.32 | 2019 | |
| Alk-Abello, INC | $15.44 | 2025 | Neffy |
| Mayne Pharma Commercial LLC | $14.30 | 2025 | |
| Allergan, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han-Jong Koh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.